Application of nanotechnology in cancer therapy and imaging

CA Cancer Journal for Clinicians

Volumn 58, Issue 2, 2008, Pages 97-110

  Wang, Xu ^a   Yang, Lily ^a   Chen, Zhuo ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; IRON OXIDE; NANOPARTICLE; PACLITAXEL; PACLITAXEL POLIGLUMEX; QUANTUM DOT;

ANGIOGENESIS; BIOCOMPATIBILITY; BREAST CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; KAPOSI SARCOMA; MOLECULAR IMAGING; MULTIDRUG RESISTANCE; NANODEVICE; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 42049110950     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/CA.2007.0003     Document Type: Review

References (155)

1. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005;2:369-381.
2. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171.
3. Li KC, Pandit SD, Guccione S, Bednarski MD. Molecular imaging applications in nanomedicine. Biomed Microdevices 2004;6:113-116.
4. Iagaru A, Masamed R, Keesara S, Conti PS. Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 2007;21:33-38.
5. Kjaer A. Molecular imaging of cancer using PET and SPECT. Adv Exp Med Biol 2006;587:277-284.
6. Montet X, Montet-Abou K, Reynolds F, et al. Nanoparticle imaging of integrins on tumor cells. Neoplasia 2006;8:214-222.
7. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-693.
8. Schellenberger EA, Bogdanov A Jr, Petrovsky A, et al. Optical imaging of apoptosis as a biomarker of tumor response to chemotherapy. Neoplasia 2003;5:187-192.
9. Atri M. New technologies and directed agents for applications of cancer imaging. J Clin Oncol 2006;24:3299-3308.
10. Liu M, Kono K, Fréchet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release 2000;65:121-131.
11. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001;53:283-318.
12. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21:1184-1191.
13. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-763.
14. Fassas A, Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 2005;46:795-802.
15. Matsumura Y. Micelle carrier system in clinical trial [in Japanese]. Nippon Rinsho 2006;64:316-321.
16. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004;15:517-525.
17. Charrois GJ, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663:167-177.
18. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-1822.
19. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006;95:822-828.
20. Rosenthal DI, Yom SS, Liu L, et al. A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs 2002;20:343-349.
21. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001;12:493-496.
22. Neville ME, Boni LT, Pflug LE, et al. Biopharmaceutics of liposomal interleukin 2, oncolipin. Cytokine 2000;12:1691-1701.
23. Ciuleanu T, Diculescu M, Hoepffner NM, et al. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers. Invest New Drugs 2007;25:385-390.
24. Clamp AR, Schöffski P, Valle JW, et al. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2007 May 23;[Epub ahead of print].
25. Guo W, Johnson JL, Khan S, et al. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study. Anal Biochem 2005;336:213-220.
26. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2004;26:639-663.
27. Pal A, Khan S, Wang YF, et al. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. Anticancer Res 2005;25:331-341.
28. Seiden MV, Muggia F, Astrow A, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004;93:229-232.
29. Dragovich T, Mendelson D, Kurtin S, et al. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 2006;58:759-764.
30. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005;16:691-707.
31. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-360.
32. Allison SD. Liposomal drug delivery. J Infus Nurs 2007;30:89-95.
33. Papahadjopoulos D, Gabizon A. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res 1990;343:85-93.
34. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994;15:215-220.
35. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211-1217.
36. Noble CO, Kirpotin DB, Hayes ME, et al. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 2004;8:335-353.
37. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004;10:2981-2989.
38. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 2004;56:1177-1192.
39. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res 2004;10:1100-1111.
40. Abra RM, Bankert RB, Chen F, et al. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res 2002;12:1-3.
41. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95-99.
42. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-1181.
43. Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60:6942-6949.
44. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-7194.
45. Hatakeyama H, Akita H, Maruyama K, et al. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int J Pharm 2004;281:25-33.
46. Eliaz RE, Nir S, Marty C, Szoka FC Jr. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004;64:711-718.
47. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 2004;95:608-613.
48. Gaur U, Sahoo SK, De TK, et al. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 2000;202:1-10.
49. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003;42:463-478.
50. Laverman P, Carstens MG, Storm G, Moghimi SM. Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim Biophys Acta 2001;1526:227-229.
51. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263:1600-1603.
52. Rawat M, Singh D, Saraf S, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 2006;29:1790-1798.
53. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005;3:348-349.
54. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-1053.
55. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
56. Richards DA, Richards P, Bodkin D, et al. Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study. Clin Lung Cancer 2005;7:215-220.
57. Boddy AV, Plummer ER, Todd R, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005;11:7834-7840.
58. Bissett D, Cassidy J, de Bono JS, et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br J Cancer 2004;91:50-55.
59. Sarapa N, Britto MR, Speed W, et al. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma. Cancer Chemother Pharmacol 2003;52:424-430.
60. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999;5:83-94.
61. Albain KS, Belani CP, Bonomi P, et al. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 2006;7:417-419.
62. Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 2004;91:1775-1781.
63. Thomson AH, Vasey PA, Murray LS, et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. Br J Cancer 1999;81:99-107.
64. Bilim V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr Opin Mol Ther 2003;5:326-330.
65. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-1676.
66. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 2001;12:315-323.
67. Rademaker-Lakhai JM, Terret C, Howell SB, et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004;10:3386-3395.
68. Campone M, Rademaker-Lakhai JM, Bennouna J, et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother Pharmacol 2007;60:523-533.
69. Van der Schoot SC, Nuijen B, Sood P, et al. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. Pharmazie 2006;61:835-844.
70. Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993;11:187-195.
71. Shiose Y, Kuga H, Yamashita F, Hashida M. Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. J Pharm Biomed Anal 2007;43:1290-1296.
72. Soepenberg O, de Jonge MJ, Sparreboom A, et al. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin Cancer Res 2005;11:703-711.
73. Ochi Y, Shiose Y, Kuga H, Kumazawa E. A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951. Cancer Chemother Pharmacol 2005;55:323-332.
74. Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003;55:217-250.
75. Rowinsky EK, Rizzo J, Ochoa L, et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003;21:148-157.
76. Duncan R, Vicent MJ, Greco F, Nicholson RI. Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer 2005;12(suppl):S189-S199.
77. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006;24:39-47.
78. Dipetrillo T, Milas L, Evans D, et al. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol 2006;29:376-379.
79. Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-976.
80. Jain TK, Morales MA, Sahoo SK, et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm 2005;2:194-205.
81. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-4646.
82. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
83. Edens HA, Levi BP, Jaye DL, et al. Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J Immunol 2002;169:476-486.
84. Sledge GW Jr, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003;39:1668-1675.
85. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004;56:1649-1659.
86. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-593.
87. Cuenca AG, Jiang H, Hochwald SN, et al. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 2006;107:459-466.
88. Northfelt DW, Martin FJ, Working P, et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996;36:55-63.
89. Netti PA, Roberge S, Boucher Y, et al. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996;52:27-46.
90. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 2003;63:4062-4066.
91. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 1980;210:1253-1255.
92. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950-6957.
93. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-4255.
94. Omelyanenko V, Gentry C, Kopeckova P, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 1998;75:600-608.
95. Omelyanenko V, Kopeckova P, Gentry C, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J Drug Target 1996;3:357-373.
96. Ulbrich K, Etrych T, Chytil P, et al. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 2004;12:477-489.
97. Wachters FM, Groen HJ, Maring JG, et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours. Br J Cancer 2004;90:2261-2267.
98. Goren D, Horowitz AT, Zalipsky S, et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-1756.
99. Guillemard V, Uri Saragovi H. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene 2004;23:3613-3621.
100. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 2004;4:313-326.
101. Pechar M, Ulbrich K, Subr V, et al. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. Bioconjug Chem 2000;11:131-139.
102. Lu ZR, Gao SQ, Kopeckova P, Kopecek J. Modification of cyclosporin A and conjugation of its derivative to HPMA copolymers. Bioconjug Chem 2001;12:129-133.
103. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev 2002;54:695-713.
104. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 2000;41:147-162.
105. Ni S, Stephenson SM, Lee RJ. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells. Anticancer Res 2002;22:2131-2135.
106. Backer MV, Gaynutdinov TI, Aloise R, et al. Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery. Protein Expr Purif 2002;26:455-461.
107. Backer MV, Aloise R, Przekop K, et al. Molecular vehicles for targeted drug delivery. Bioconjug Chem 2002;13:462-467.
108. Pardridge WM. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res 1998;23:635-644.
109. Gao X, Chen J, Tao W, et al. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int J Pharm 2007;340:207-215.
110. Ferry DR, Traunecker H, Kerr DJ. Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 1996;32A:1070-1081.
111. McDevitt CA, Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 2007;113:429-441.
112. Pepin X, Attali L, Domrault C, et al. On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. J Chromatogr B Biomed Sci Appl 1997;702:181-191.
113. Northfelt DW, Dezube BJ, Thommes JA, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997;15:653-659.
114. Mamot C, Drummond DC, Hong K, et al. Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Updat 2003;6:271-279.
115. Batrakova EV, Li S, Elmquist WF, et al. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001;85:1987-1997.
116. Batrakova EV, Li S, Vinogradov SV, et al. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001;299:483-493.
117. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005;103:405-418.
118. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm 2005;2:373-383.
119. Weissleder R. Molecular imaging in cancer. Science 2006;312:1168-1171.
120. Gao X, Yang L, Petros JA, et al. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol 2005;16:63-72.
121. Lee JH, Huh YM, Jun YW, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007;13:95-99.
122. Wang W, Ke S, Wu Q, et al. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 2004;3:343-351.
123. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol Cancer Ther 2003;2:489-496.
124. Begent RH, Verhaar MJ, Chester KA, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 1996;2:979-984.
125. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymphnode metastases in prostate cancer. N Engl J Med 2003;348:2491-2499.
126. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13:372-377.
127. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006;3:311-324.
128. Gaucher G, Dufresne MH, Sant VP, et al. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005;109:169-188.
129. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998;281:2016-2018.
130. Soltesz EG, Kim S, Laurence RG, et al. Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. Ann Thorac Surg 2005;79:269-277.
131. Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006;6:669-676.
132. Sjögren CE, Johansson C, Naevestad A, et al. Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging 1997;15:55-67.
133. Wunderbaldinger P, Josephson L, Bremer C, et al. Detection of lymph node metastases by contrast-enhanced MRI in an experimental model. Magn Reson Med 2002;47:292-297.
134. Högemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug Chem 2000;11:941-946.
135. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004;17:484-499.
136. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997;7:1140-1145.
137. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. J Magn Reson Imaging 1994;4:659-668.
138. Maier-Hauff K, Rothe R, Scholz R, et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007;81:53-60.
139. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63:6838-6846.
140. Lewin M, Carlesso N, Tung CH, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-414.
141. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49:403-408.
142. Moore A, Marecos E, Bogdanov A Jr, Weissleder R. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000;214:568-574.
143. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63:2723-2727.
144. Choi H, Choi SR, Zhou R, et al. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol 2004;11:996-1004.
145. Nasongkla N, Bey E, Ren J, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006;6:2427-2430.
146. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
147. Ciordia S, de Los Rios V, Albar JP. Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol 2006;8:566-580.
148. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
149. Clapp AR, Medintz IL, Uyeda HT, et al. Quantum dot-based multiplexed fluorescence resonance energy transfer. J Am Chem Soc 2005;127:18212-18221.
150. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005;4:435-446.
151. Fountaine TJ, Wincovitch SM, Geho DH, et al. Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Mod Pathol 2006;19:1181-1191.
152. Cho YW, Park SA, Han TH, et al. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials 2007;28:1236-1247.
153. Seo WS, Lee JH, Sun X, et al. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat Mater 2006;5:971-976.
154. Koo YE, Fan W, Hah H, et al. Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Appl Opt 2007;46:1924-1930.
155. Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006;12:6677-6686.